PH12022550500A1 - Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof - Google Patents

Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof

Info

Publication number
PH12022550500A1
PH12022550500A1 PH1/2022/550500A PH12022550500A PH12022550500A1 PH 12022550500 A1 PH12022550500 A1 PH 12022550500A1 PH 12022550500 A PH12022550500 A PH 12022550500A PH 12022550500 A1 PH12022550500 A1 PH 12022550500A1
Authority
PH
Philippines
Prior art keywords
ophthalmic composition
menthol
preparation
cyclosporine
nanoemulsion ophthalmic
Prior art date
Application number
PH1/2022/550500A
Other languages
English (en)
Inventor
Dae Hun Kim
Joon Youb Lee
Hyun Won Seo
Youn Jae Shin
Original Assignee
Taejoon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taejoon Pharmaceutical Co Ltd filed Critical Taejoon Pharmaceutical Co Ltd
Publication of PH12022550500A1 publication Critical patent/PH12022550500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/550500A 2019-09-09 2020-09-04 Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof PH12022550500A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190111776 2019-09-09
PCT/KR2020/011977 WO2021049825A1 (ko) 2019-09-09 2020-09-04 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Publications (1)

Publication Number Publication Date
PH12022550500A1 true PH12022550500A1 (en) 2023-10-18

Family

ID=74867274

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550500A PH12022550500A1 (en) 2019-09-09 2020-09-04 Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof

Country Status (8)

Country Link
US (1) US12576126B2 (cg-RX-API-DMAC7.html)
EP (1) EP4029493A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548221A (cg-RX-API-DMAC7.html)
KR (2) KR102273481B1 (cg-RX-API-DMAC7.html)
CN (1) CN114364372A (cg-RX-API-DMAC7.html)
CA (1) CA3149270A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021049825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190283A1 (ja) * 2022-03-28 2023-10-05 中外製薬株式会社 ポリオキシエチレン構造を含む油性成分を含有する化合物製剤
IL294896B1 (en) * 2022-07-20 2026-06-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical administration of cyclosporine to the eye

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635796B2 (en) 1990-03-16 2003-10-21 Sevenson Environmental Services, Inc. Reduction of leachability and solubility of radionuclides and radioactive substances in contaminated soils and materials
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
CA2426164C (en) 2001-06-27 2009-08-11 Nokia Corporation Method and system for bearer authorization in a wireless communication network
AU2002357604A1 (en) 2001-12-21 2003-07-09 Senju Pharmaceutical Co., Ltd. Eye drops
PT1487416E (pt) 2002-03-26 2010-01-25 Teva Pharma Micropartículas de fármacos
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
AU2004212989A1 (en) * 2003-02-20 2004-09-02 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
US20070008894A1 (en) 2004-10-19 2007-01-11 Idt Corporation Telecommunications-based link monitoring system
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
KR100669510B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 사이크로스포린을 함유한 나노 에멀젼 농축액 조성물 및 그제조방법
CN101244256A (zh) * 2007-02-16 2008-08-20 中国科学院上海药物研究所 一种环孢菌素a眼用微/亚微乳原位凝胶制剂及其制备方法
EP3078385A1 (en) * 2010-05-25 2016-10-12 Allergan, Inc. Cyclosporin emulsions
WO2012015211A2 (ko) * 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
KR20130100290A (ko) * 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
US8455991B2 (en) 2010-09-24 2013-06-04 Stats Chippac Ltd. Integrated circuit packaging system with warpage control and method of manufacture thereof
WO2013008714A1 (ja) * 2011-07-08 2013-01-17 ロート製薬株式会社 眼科用水性組成物
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
KR101492447B1 (ko) * 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
US10963928B2 (en) 2014-08-21 2021-03-30 Stubhub, Inc. Crowdsourcing seat quality in a venue
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
KR20170032808A (ko) * 2015-09-15 2017-03-23 주식회사 엘지생활건강 멘톨 또는 멘톨 유도체를 포함하는 용해성 미세바늘 패치
CN105726479B (zh) * 2016-03-24 2018-06-22 北京茗泽中和药物研究有限公司 环孢素眼用乳剂
CA3285799A1 (en) * 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US11583496B2 (en) * 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
WO2019111917A1 (ja) * 2017-12-07 2019-06-13 ライオン株式会社 水性眼科用組成物及びエマルション粒子の微粒化方法
CN110090294A (zh) * 2019-04-09 2019-08-06 嘉兴市爵拓科技有限公司 具有改善的干燥保护和保留的眼用组合物

Also Published As

Publication number Publication date
EP4029493A4 (en) 2023-10-04
CN114364372A (zh) 2022-04-15
KR20210030215A (ko) 2021-03-17
WO2021049825A1 (ko) 2021-03-18
KR102638866B1 (ko) 2024-02-21
KR102273481B1 (ko) 2021-07-06
KR20210084389A (ko) 2021-07-07
EP4029493A1 (en) 2022-07-20
US20240041974A1 (en) 2024-02-08
JP2022548221A (ja) 2022-11-17
US12576126B2 (en) 2026-03-17
CA3149270A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
WO2017158365A3 (en) Ophthalmic delivery device and ophthalmic active agent containing compositions
JOP20190193B1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
EP4279063A3 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
MY194787A (en) External agent for skin or mucous membrane and production method thereof, and base for external agent for skin or mucous membrane
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
BRPI0708802A2 (pt) inserto corneal intra-estromal pré-formado para anormalidades ou distrofias corneais
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
PH12022553548A1 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
MX420447B (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona
WO2021240376A3 (en) Ophthalmic nanoemulsion compositions
RU2012120096A (ru) Офтальмологические препараты на основе bdnf (нейротрофического фактора головного мозга) и их применение
KR102638866B1 (ko) 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
BR112023003144A2 (pt) Derivado de pirrolopiridina e uso do mesmo
EP4559529A3 (en) Isocyclosporin a for topical treatment of ocular diseases
WO2020091287A8 (ko) 윤기 지속형 화장료 조성물
WO2003011299A3 (en) Treatment of ocular hypertension and glaucoma